RLYB•benzinga•
Rallybio Initiates Dosing In Phase 1 Confirmatory PK/PD Study Evaluating RLYB116, Subcutaneously Injected C5 Inhibitor
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 12, 2025 by benzinga